STANFORD, CA – April 24, 2024 – In a discovery that redefines our understanding of cancer immunology, scientists have uncovered a surprising and critical function for erythropoietin (EPO), a protein primarily known for stimulating red blood cell production. Identified nearly four decades ago for its hematopoietic properties, EPO has now been found to play a pivotal role in dampening the immune system’s response to cancer, effectively creating an immune-resistant environment within tumors. This groundbreaking research, published online today in Science, reveals that blocking EPO’s activity can transform previously "cold" or immune-resistant liver tumors in mice into "hot" tumors, teeming with cancer-fighting immune cells. When combined with existing immunotherapy, this novel approach led to complete regression of established tumors and extended survival for the duration of the experimental period.
The implications of this discovery are profound, offering a potential new avenue for treating a wide array of cancers that currently evade conventional immunotherapies. For years, EPO has been viewed solely through the lens of its erythropoietic function, even carrying a black box warning from the Food and Drug Administration (FDA) since 2007 due to observed tumor acceleration in anemic cancer patients receiving EPO. This new research not only clarifies the long-suspected link between EPO and cancer progression but fundamentally recontextualizes it within the realm of immune evasion.
"This is a fundamental breakthrough in our understanding of how the immune system is turned off and on in cancer," stated Dr. Edgar Engleman, MD, PhD, a distinguished professor of pathology and medicine and senior author of the research. His palpable excitement underscores the significance of the findings. "I could not be more excited about this discovery, and I hope treatments that target the mechanism we uncovered will quickly move forward to human trials." Dr. David Kung-Chun Chiu, PhD, a basic life research scientist and lead author of the study, spearheaded the intricate experimental work that led to this revelation.
The Journey of Discovery: Unraveling EPO’s Immunosuppressive Power
The path to this discovery was one of persistent inquiry and a willingness to challenge long-held assumptions. For decades, EPO has been celebrated for its vital role in the body’s response to low oxygen levels (hypoxia) by stimulating the bone marrow to produce more red blood cells, thereby increasing oxygen-carrying capacity. This physiological function has made synthetic EPO a crucial therapeutic for anemia, particularly in patients with kidney disease or undergoing chemotherapy. However, a darker side to EPO’s interaction with cancer began to emerge years ago, prompting regulatory caution.
Historical Warnings Re-examined: EPO and Tumor Growth
More than a decade ago, clinical observations revealed a disturbing trend: giving exogenous EPO to anemic cancer patients, intended to improve their quality of life, often accelerated tumor growth. This counterintuitive finding led to the FDA’s decision in 2007 to mandate a black box warning on EPO-stimulating agents, cautioning against their use in people with cancers. The mechanism behind this acceleration remained largely enigmatic, though correlations between higher levels of naturally occurring EPO and its receptor (EPOR) in tumors and poorer patient prognoses were consistently observed across various cancer types.
"Those old reports showed clearly that the more EPO or EPOR there was in tumors, the worse off the patients were," Dr. Engleman explained. "But the connection between EPO and cancer immunity was never made until now. In fact, it took a long time and a lot of experiments to convince us that EPO plays a fundamental role in blocking the immune response to cancer, because EPO is so well established as a red blood cell growth factor." This intellectual inertia, born from EPO’s well-understood hematopoietic function, obscured its immunomodulatory role for years. The current research provides the missing piece of this complex puzzle, shifting the focus from EPO’s direct effect on tumor cells to its indirect, yet profound, impact on the tumor’s immune microenvironment.
Crafting Models: Probing Liver Cancer’s Immune Evasion
The research team, led by Dr. Chiu, embarked on a sophisticated experimental journey utilizing advanced genome editing techniques to create multiple mouse models of liver cancer. These models were meticulously designed to faithfully recapitulate the specific mutations, histological features, and responses to approved therapies observed in distinct subtypes of human liver cancers. Tumor formation was induced through two primary methods: either by injecting a combination of DNA encoding proteins associated with liver cancer into the animals’ tail veins or by directly implanting liver cancer cells into the animals’ livers. This comprehensive modeling approach allowed the researchers to explore the intricate dynamics of tumor development and treatment response under controlled conditions.
A central focus of their investigation was the efficacy of existing immunotherapies, specifically those targeting the programmed cell death protein 1 (PD-1) pathway. PD-1 is a checkpoint molecule found on immune cells, particularly T cells. Cancer cells often exploit this pathway by expressing ligands that bind to PD-1, effectively "turning off" the T cells and allowing the tumor to evade immune surveillance. Anti-PD-1 therapies, such as the commercially available Keytruda, work by blocking this interaction, thereby reactivating T cells to attack the cancer. These therapies have revolutionized the treatment of several cancers, including melanoma, Hodgkin’s lymphoma, and certain lung cancers, transforming patient outcomes for many. However, a significant proportion of tumors, notably most liver, pancreas, colon, breast, and prostate cancers, remain stubbornly resistant to these treatments. Understanding this resistance was a key driver of the study.
From "Cold" to "Hot": The Transformative Power of EPO Blockade
The researchers observed, consistent with human liver cancers, that certain combinations of genetic mutations in their mouse models led to the development of liver tumors that were largely ignored by the immune system. These tumors, colloquially termed "cold" or "immune-privileged," exhibited a scarcity of T cells within their microenvironment. Consequently, when these animals were treated with anti-PD-1 therapy, the tumors showed no significant shrinkage, demonstrating their inherent resistance.
In stark contrast, other genetic alterations resulted in "hot" or "inflamed" tumors. These tumors were replete with T cells and, crucially, proved highly sensitive to anti-PD-1 treatment, which effectively triggered the T cells to launch a robust attack against the cancerous cells, leading to tumor regression. The distinction between "cold" and "hot" tumors is a critical concept in modern cancer immunology, representing a fundamental challenge in making immunotherapy universally effective.
Hypoxia, EPO, and the Immunosuppressive Cascade
It was in the analysis of these divergent tumor types that the unexpected connection to EPO emerged. The "cold" tumors, characterized by their immune evasion, displayed significantly elevated levels of EPO compared to their "hot" counterparts. The researchers hypothesized that this increase was likely driven by the oxygen-poor microenvironment—a condition known as hypoxia—prevalent within these immune-resistant tumors. Hypoxia is a common feature of rapidly growing tumors, as their expansion often outstrips the supply of oxygen from the existing vasculature. In response to this low oxygen stress, cancer cells activate specific molecular pathways that, in turn, ramp up the production and secretion of EPO. The conventional wisdom dictated that this EPO production was an adaptive mechanism, aimed at stimulating red blood cell formation to combat the localized oxygen deprivation.
"Hypoxia in tumors has been studied for decades," Dr. Engleman reflected. "It just didn’t dawn on anyone, including me, that EPO could be doing anything in this context other than serving as a red blood cell growth factor." This long-standing blind spot highlights how deeply ingrained the primary understanding of EPO was within the scientific community.
Driven by this intriguing, unexpected correlation, the researchers delved into existing public databases to validate their observations. They confirmed that elevated levels of EPO were indeed consistently correlated with poorer survival outcomes in human patients suffering from a wide range of cancers, including those of the liver, kidney, breast, colon, and skin. This strong epidemiological link further solidified the hypothesis that EPO might play a more sinister role in cancer than previously understood.
The experimental validation of EPO’s role was even more striking. The team meticulously manipulated the ability of tumor cells to produce EPO in their mouse models. They found that mutations that had previously led to the development of "cold" tumors now resulted in "hot" tumors when those tumors were genetically modified to be incapable of producing EPO. Conversely, "hot" tumors that had previously been successfully eradicated by the immune system thrived and grew unchecked when they were engineered to produce elevated levels of EPO. This direct cause-and-effect relationship unequivocally demonstrated EPO’s critical role in mediating immune suppression within the tumor microenvironment.
Macrophages: Key Mediators of EPO’s Immune Dampening
The question then became: how exactly does EPO exert its immunosuppressive effect? Extensive and exhaustive research revealed a precise cellular mechanism. In "cold" tumors, the tumor cells themselves produce and secrete EPO. This secreted EPO then binds to specific receptors (EPOR) located on the surface of immune cells called macrophages. Macrophages are versatile immune cells that can adopt various phenotypes, some of which are pro-inflammatory and anti-tumorigenic, while others are immunosuppressive and pro-tumorigenic. The binding of EPO to EPOR on macrophages was found to induce a critical shift in their function. These macrophages were reprogrammed into an immunosuppressive state, effectively "shooing away" cancer-killing T cells and actively dampening their cytotoxic activity. This EPO-moderated crosstalk between tumor cells and macrophages emerged as a central mechanism by which tumors create an immune-privileged sanctuary for themselves.
Synergistic Breakthrough: Combining EPO Blockade with Immunotherapy
The identification of this EPO-macrophage axis presented a compelling therapeutic target. The researchers hypothesized that simultaneously blocking the EPO signaling pathway and the PD-1 pathway could create a powerful synergistic effect, overcoming immune resistance and unleashing a potent anti-cancer response. The experimental results unequivocally supported this hypothesis.
Dramatic Regression: A Glimpse into Future Treatments
In these crucial combinatorial experiments, mice bearing "cold" liver tumors that received either a control treatment or anti-PD-1 therapy alone showed dismal outcomes, with none surviving beyond eight weeks after tumor induction. This stark reality highlighted the inherent resistance of these tumors to conventional immunotherapy.
However, the picture dramatically changed when the EPO pathway was disrupted. In mice whose macrophages were genetically engineered to be unable to produce the EPO receptor, a significant proportion (40%) lived for 18 weeks after tumor induction, at which point the experiment was terminated. This indicated that simply removing the EPO-mediated immunosuppression provided a substantial survival benefit. The most remarkable results, however, came from the combination therapy. When anti-PD-1 treatment was administered to mice lacking the EPO receptor on their macrophages, a stunning outcome was observed: all animals lived for the entire duration of the experiment, demonstrating complete and durable tumor regression.
"It’s simple," Dr. Engleman stated, encapsulating the elegance and impact of the findings. "If you remove this EPO signaling, either by lowering the hormone levels or by blocking the receptors on the macrophages, you don’t just get a reduction in tumor growth, you get tumor regression along with sensitivity to anti-PD-1 treatment." This represents a truly transformative potential, offering a strategy to convert a large segment of currently untreatable cancers into ones highly responsive to existing immunotherapies.
Implications and the Path Forward: Translating Bench to Bedside
The discovery of EPO’s critical role in cancer immune evasion is poised to have a profound impact on oncology. It not only clarifies a long-standing mystery surrounding EPO’s adverse effects in cancer patients but also opens up an entirely new therapeutic frontier.
Broad Applicability Across Cancer Types
While the current work was primarily conducted in mouse models of liver cancer, the strong indications of EPO’s similar role in many types of human cancers, supported by correlational data from patient databases, suggest broad applicability. Liver, kidney, breast, colon, and skin cancers were all noted to show poorer patient prognosis with elevated EPO levels. This universality implies that targeting EPO signaling could be a foundational strategy for overcoming immune resistance across a wide spectrum of solid tumors that are currently unresponsive to checkpoint inhibitors. The ability to turn "cold" tumors "hot" is one of the holy grails of cancer immunology, and this research provides a clear, actionable pathway to achieve it.
Designing the Next Generation of Cancer Therapies
Dr. Engleman and his colleagues are already actively designing new therapeutic strategies targeting EPO signaling in human cancers. Several approaches are being considered:
- Non-specific EPO targeting: This involves blocking the EPO protein itself. While potentially effective, this strategy carries a known side effect: anemia, as EPO is crucial for red blood cell production. However, Dr. Engleman speculates that for patients facing aggressive, otherwise untreatable cancers, anemia might be an "acceptable trade-off" for an effective cancer therapy. This would require careful clinical management but could offer a rapid path to trials given existing knowledge of EPO inhibitors.
- Selective EPOR blockade on macrophages: A more precise approach would involve developing drugs that specifically block the EPO receptors only on the surfaces of macrophages within the tumor microenvironment. This targeted strategy would aim to mitigate systemic side effects like anemia, preserving EPO’s essential hematopoietic function while disabling its immunosuppressive role in cancer. This approach would likely require novel drug development, focusing on macrophage-specific delivery or receptor targeting.
- Combination therapies: The success of combining EPO pathway blockade with anti-PD-1 therapy in mice strongly advocates for this strategy in human trials. This synergistic effect suggests that EPO modulators could serve as potent "sensitizers" for existing immunotherapies, expanding their reach and efficacy.
Ethical Considerations and the Promise of Precision
The historical context of EPO use in cancer patients, particularly the FDA black box warning, underscores the critical need for careful and ethical clinical translation. The new understanding provided by this research transforms the interpretation of those earlier observations from a direct tumor-promoting effect of EPO to an immune-suppressive one. This re-contextualization is vital for designing safe and effective human trials. The promise of precision medicine, where therapies are tailored to the specific characteristics of a patient’s tumor, is further bolstered by this discovery. Identifying patients with high tumor hypoxia and elevated EPO levels could enable selection for EPO-targeting treatments.
"I continue to be amazed by this finding," Dr. Engleman concluded. "Not every tumor is going to respond in the same way, but I’m very optimistic that this discovery will lead to powerful new cancer therapies."
Collaborative Science and Financial Backing
This ambitious research project was the result of significant collaborative efforts, with researchers from the New York Blood Center and the pharmaceutical company ImmunEdge Inc. contributing their expertise. The study received substantial financial backing from prestigious institutions, including the National Institutes of Health, through grants R01CA262361, P01CA244114, U54CA2745115, and P01HL149626.
It is also important to note the potential for direct commercial translation of this research. Dr. Chiu is a cofounder of ImmunEdge Inc., and Dr. Engleman is a founder, shareholder, and board member of the same company. Both Dr. Chiu and Dr. Engleman are Stanford-affiliated inventors of a patent application (PCT/US2023/063997) titled "EPO receptor agonists and antagonists," highlighting the immediate trajectory toward developing therapeutic agents based on this seminal discovery. This intricate interplay between academic research, commercial enterprise, and intellectual property underscores the rapid pace at which this fundamental breakthrough is moving toward real-world applications for cancer patients. The journey from a decades-old mystery to a potential new class of cancer therapies has truly begun.
About the Author
